Biography & Research:
Gerald Novak, M.D. is a Senior Director in the Neurology division at Janssen R&D. He obtained his M.D. from the Albert Einstein College of Medicine in 1977, and his medical training included a pediatric residency at Children's Hospital of Philadelphia, and fellowships in child neurology and clinical neurophysiology at Albert Einstein. He joined Janssen R&D in 2001, and has participated in the late stage development of several compounds for the treatment of Alzheimer disease, including galantamine and bapineuzumab. He has conytributed his efforts to several public-private partnerships, including the the Coalition Against Major Diseases, Alzheimer Disease Neuroimaging Initiative (currently as chairman-elect of the ADNI Private Partners Scientific Board), the European Medical Information Framework-AD, and the European Prevention of AD project. He is a member of the American Academy of Neurology and of the International Society to Advance Alzheimer's Research and Treatment. His current focus of interest is in the integration of multimodal biomarker data with clinical outcomes in preclinical AD.